What Beriglobin Treats: Main Uses and Benefits

Beriglobin is applied across domains where additional symptomatic support is needed, primarily in clinical settings that involve acute or unstable symptom patterns. Its core benefits help patients cope more steadily with difficult episodes across multiple clinical contexts.

The medication is commonly used across conditions characterized by periods of heightened symptoms, including supportive management for antibody deficiency syndromes, managing symptoms related to acute viral exposure like Hepatitis A, and providing assistance in challenging symptomatic phases such as radiogenic mucositis.

“The goal is to provide supportive relief when symptoms interfere with routine activities.”

It helps address symptom clusters that may become intense or disruptive, focusing on symptoms that create noticeable functional strain. The therapy is relevant for easing the overall symptom load and assists with maintaining functional stability in conditions involving episodic or fluctuating manifestations.

Quick Fact: Supports Management of Symptom Clusters Associated with Noticeable Strain

Regulatory References

1. European Medicines Agency's safety overview

Beriglobin is generally approved for use across Adults, Children, and Adolescents aged 0–18 years for established replacement therapy indications, as defined in regulatory documents. However, official labeling outlines clear restrictions and populations who must not use the medicine.

---

Who Must Not Use Beriglobin (Contraindications)

Use of Beriglobin is contraindicated if you have a known hypersensitivity to Human Normal Immunoglobulin or any other component. It must not be used in individuals with isolated Immunoglobulin A (IgA) deficiency, due to the potential for developing severe allergic reactions. The medicine must not be injected into a blood vessel (intravascularly) under any circumstances. Furthermore, the intramuscular route is contraindicated for individuals with severe clotting disorders or severe thrombocytopenia.

---

Conditional Use and Restrictions

Certain populations require caution or special consideration. Advanced age is officially listed as a pre-existing risk factor for thrombotic events, along with comorbidities such as diabetes mellitus, hypertension, and a history of vascular disease. Administration to pregnant women and breastfeeding mothers must be carefully considered by a healthcare provider, as controlled clinical trial data on its use in these specific populations are currently limited.

Interactions with other medicines and products

Administration of Beriglobin, an immunoglobulin product, may affect the efficacy of certain vaccines and interfere with specific diagnostic tests. These interactions are due to the passive transfer of antibodies.

Interactions Affecting Vaccines

Beriglobin may impair the effectiveness of live attenuated virus vaccines, including measles, rubella, mumps, and varicella vaccines. Official regulatory documentation mandates specific spacing requirements between immunoglobulin administration and vaccination:

• Required Delay: Vaccination with a live attenuated virus vaccine should be deferred for a minimum period of at least three months after receiving Beriglobin.
• Measles Vaccine: The potential impairment of the measles vaccine's efficacy can persist for up to one year. If the measles vaccine is administered after Beriglobin, the patient's antibody status should be checked to confirm vaccine effectiveness.

Interactions Affecting Serological Testing

The temporary rise in passively transferred antibodies following Beriglobin injection may lead to misleading positive results in serological testing. Specifically, the passive transmission of antibodies to erythrocyte antigens (such as A, B, and D) may interfere with some red cell allo-antibody tests, including the Coombs test. When interpreting serological results, healthcare providers must consider the amount of immunoglobulin administered, the time elapsed since the injection, and the sensitivity of the test method.

Passive Transfer for Rapid Antigen Clearance

This mechanism centers on the F( ab')2 regions of the transferred polyclonal antibodies, which rapidly bind to circulating antigens and toxins from pathogens. This binding action initiates neutralization and opsonization, leading to the facilitation of pathogen and toxin clearance from the bloodstream.

---

Immune Receptor and Pathway Modulation

This domain is driven by the Fc portion of the concentrated IgG interacting with the host's Fc Receptors ( Fcgamma R) on immune effector cells. This interaction causes a competitive blockade that adjusts the activation threshold of key immune cells, resulting in the modulation of systemic inflammatory signaling and T cell activity.

---

Mechanism Persistence and Functional Synergy

The functional duration of the transferred antibodies is preserved through binding to the Neonatal Fc Receptor ( FcRn), which protects the IgG from rapid catabolic degradation. Furthermore, the synergy of the preparation’s multiple IgG subclasses (e.g., IgG1, IgG2, IgG3, IgG4) results in the synergistic expression of both defense and modulation mechanisms across various physiological environments.

Administration Overview

Beriglobin is a solution containing human normal immunoglobulin. The administration process is conducted by healthcare professionals who ensure that the solution is at approximately room temperature or body temperature before use. This preparation helps maintain the integrity of the proteins within the solution.

Method of Administration

Intramuscular Injection

This medication is specifically intended for intramuscular administration. Healthcare providers typically select a large muscle mass for the injection site to facilitate proper absorption.

Precautions During Administration

To ensure the solution enters the muscle tissue correctly, the healthcare professional will perform a check during the injection process to verify that a blood vessel has not been entered. If a large total volume is required, the dose may be divided and administered at different anatomical sites.

Observation Period

Following the administration of Beriglobin, individuals are typically kept under medical observation. This period allows healthcare providers to monitor for any immediate physiological responses to the injection. The duration of this observation is determined by clinical protocols and the specific needs of the individual.

Research Evidence / Overview of Studies for Beriglobin

The research evidence for Human Normal Immunoglobulin (Beriglobin) is derived from different study types, describing what research examined and where uncertainty remains.

Evidence Supporting Replacement Therapy for Antibody Deficiency Syndromes

For patients whose bodies cannot produce sufficient protective antibodies, research consists of long-term observational patient cohorts and clinical trials. Studies monitored outcomes related to physiological strain, tracking infection frequency and Immunoglobulin G (IgG) trough levels in the bloodstream. The body of evidence supporting this use is extensive and categorized as High by regulatory bodies. Limitations include the reliance on large observational cohorts and challenges in establishing standardized measurement protocols for long-term complications like bronchiectasis.

Evidence Supporting Prophylaxis Against Hepatitis A Infection

This part reviews the research that was studied for providing temporary, passive immune support against Hepatitis A. Evidence includes reviews of historical observational data and serological analyses. Researchers measured the prevention of clinically apparent Hepatitis A infection and confirmed the transfer of protective antibody levels. The duration of this passive immune state was observed in some studies, where the need for repeat administration was studied for exposures lasting 4 to 6 months. Controlled trials on use in human pregnancy are not available, and data for this specific group remain insufficient.

Evidence Supporting Supportive Management of Radiogenic Mucositis

The research explored this use in conditions involving periods of heightened symptoms through specific Randomized, Placebo-Controlled, Double-Blind (RCT) trials and retrospective analyses. Researchers examined outcomes related to physical discomfort, monitoring mucosa severity and pain intensity. Findings were mixed regarding the optimal way to use the medicine. The primary randomized study had a short initial follow-up phase of around seven days, meaning intermediate or long-term outcomes are not fully established.

Research Gaps and Specific Population Evidence

For ongoing therapies, evidence is derived from long-term observational settings across many years, as long-term effects are not fully established through short-term RCTs. Research has explored effects in adults, children, and adolescents, but data for certain groups remain insufficient, particularly for human pregnancy. Overall, evidence quality varies across studies, and research provides context but not individual predictions.

Key Studies & References

1. Immunoglobulin replacement therapy | Immune Deficiency Foundation (IDF) Clinical Guidelines
2. Hepatitis A immunoglobulin (issued 2024) - GOV.UK Public Health Management Guidance
3. BERIGLOBIN 160 mg per ml solution for injection ENG PAR (Radiogenic Mucositis and Long-term Use Data)
4. Intravenous Immunoglobulin (IVIG) - StatPearls - NCBI Bookshelf (General Immunoglobulin Information)
5. Clinical Commissioning Policy: for the use of therapeutic immunoglobulin (Ig) England (2025)

Common questions about Beriglobin (FAQ)

---

Q: How long does the protective effect of Beriglobin last?

The duration of the protective effect depends on the reason the medicine is administered. For prophylaxis (prevention) against Hepatitis A, regulatory information indicates that the need for repeat administration every two months is indicated for continuous protection during long-term exposure.

---

Q: What is the expected timeline for Beriglobin to start working?

Beriglobin is classified as a passive immunizing agent. This means it works by providing an immediate, concentrated supply of defensive antibodies, rather than requiring the body to produce them. The time to reach maximum concentration of these antibodies in the bloodstream is generally referenced as being within a few days after administration.

---

Q: Can Beriglobin be used during pregnancy?

Official documents state that controlled clinical trials on use in human pregnancy are not available. Therefore, official guidance states that administration must be carefully considered by a healthcare professional. Long-standing experience with this class of medicines, however, suggests no harmful effects are expected on the course of pregnancy.

---

Q: Is Beriglobin safe for people who are breastfeeding?

Official product information indicates that administration in breastfeeding mothers requires careful consideration by a healthcare professional. This is based on regulatory standards for this class of medicine.

---

Q: Can Beriglobin affect blood test results?

Yes, Beriglobin can temporarily affect certain diagnostic tests. The passive transfer of antibodies following injection may lead to misleading positive results in specific serological tests, such as the Coombs test and certain red cell antibody tests.

---

Q: Why do some people need more than one dose of Beriglobin?

Repeat dosing is used to ensure consistent immune support. For long-term replacement therapy, multiple doses are needed to maintain adequate Immunoglobulin G (IgG) trough levels in the bloodstream, as directed by a healthcare professional. In prophylactic use, repeat doses may be required for prolonged periods of exposure to an infectious agent.

---

Q: Is Beriglobin the same as other immune globulins?

Beriglobin is the brand name for the medicine, which contains the active ingredient Human Normal Immunoglobulin. This ingredient is part of a larger, well-recognized class of plasma-derived immunological agents used to provide passive immune support.

---

Q: Does Beriglobin contain a preservative?

Official regulatory documents typically list the excipients (inactive ingredients) for Human Normal Immunoglobulin products as glycine, sodium chloride, and water for injection. These listed ingredients do not include a preservative.

---

Q: Can a patient with a known allergy to human proteins take Beriglobin?

The medicine is contraindicated, meaning its use is restricted, in patients with a known hypersensitivity to Human Normal Immunoglobulin or any of its components. It is also restricted for patients with an isolated IgA deficiency who have formed anti-IgA antibodies, due to the officially documented risk of severe allergic reactions.

---

Q: Is Beriglobin used for people who travel internationally?

Yes, official labeling includes use for travelers in certain circumstances. The intramuscular route is indicated for Hepatitis A prophylaxis for unvaccinated individuals travelling to areas of risk.

---

Q: Are there different types or brands of Beriglobin?

The specific name and formulation may vary by region or purification method; for example, official documents reference variations such as Beriglobin P. The active ingredient remains Human Normal Immunoglobulin.

---

Q: What is the shelf life of Beriglobin?

The maximum shelf life is defined by the manufacturer and is officially specified on the outer packaging and container. The product must not be used after the expiration date printed on the pack.

---

Q: Is Beriglobin widely approved in many countries?

Regulatory information is published by health authorities in numerous countries, including the European Medicines Agency ( EMA) and the FDA, which reflects the medicine's global authorization status across major health systems.

---

Q: Is the manufacturing process for Beriglobin publicly available?

The manufacturer submits detailed, comprehensive documents on the purification and safety processes (such as the Plasma Master File) to regulatory bodies for official review. However, these documents are typically submitted for official review and not made fully public.

---

Q: Does Beriglobin affect my ability to drive or operate machinery?

Official documents contain a section addressing this topic. The section indicates that caution is required if side effects such as headache or dizziness are experienced after administration.

---

Q: Is a slight fever after the Beriglobin injection normal?

Fever is listed in official documentation as a common side effect. This means it is a common, expected effect that, according to official data, may occur in up to 1 in 10 people.

How to Store and Dispose of Beriglobin?

Strict storage conditions are required to maintain the stability and effectiveness of Beriglobin. The product must be stored under refrigerated conditions at a controlled temperature range of +2 to +8 C.

Key Storage and Stability Requirements

Constraint	Requirement
Temperature	Store at +2 to +8 C.
In-Use Stability	Contents must be used immediately after opening the ampoule.
Integrity Check	Do not use if the solution is cloudy or contains particles.
Expiry Date	Do not use after the expiration date printed on the pack and container.

Disposal

Proper disposal is required to protect the environment and maintain safety. Any unused medicine should be returned to the pharmacist or disposed of in strict accordance with local requirements for medicinal waste.